Alira Health announces its role as Strategic Advisor to Bracco Imaging S.p.A. in the Commercial Due Diligence of Blue Earth Diagnostics

Alira Health announces its role as Strategic Advisor to Bracco Imaging S.p.A. in the Commercial Due Diligence of Blue Earth Diagnostics.

Alira Health adds Bracco Imaging S.p.A to their growing list of Commercial Due Diligence clients.

FRAMINGHAM, MASSACHUSETTS – JULY 11, 2019 – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, was selected as the Strategic Advisor to Bracco Imaging S.p.A during the company’s commercial due diligence phase for their pending acquisition of Blue Earth Diagnostics, a molecular imaging company based in Oxford, UK. On June 27, Bracco announced that it had signed a definitive agreement to acquire the company, and the completion of this transaction is expected in Q3.

“We chose Alira Health to perform the commercial due diligence because of their deep expertise in the imaging space,” said Vittorio Puppo, President & CEO, and Interim Head of Corporate Business Development, Bracco. “Their knowledge of regulatory, clinical, scientific, and market dynamics made the process efficient and helped us to complete this acquisition with confidence. We look forward to welcoming the world-class Blue Earth Diagnostics team to Bracco.”

“Our clients appreciate our deep expertise, which results in a short learning curve compared to other advisories”, says Gabriele Brambilla, Chief Executive Officer of Alira Health. “Efficient, direct, and transparent opinions and analysis are critical for commercial due diligence projects. I receive calls from clients, even years later, to thank us for our recommendation to pursue, or not pursue, a particular target at a certain price or under certain conditions. Time has proven us right again and again, thanks to the expertise of our team.”

Alira Health continues to grow its commercial due diligence specialty in pharma, MedTech and digital health, and reports over $9B of consummated deal value over the past 12 months.

About Bracco Imaging S.p.A.:

Bracco Imaging S.p.A., part of The Bracco Group, is one of the world’s leading companies in the diagnostic imaging business with 2018 revenues exceeding €1 billion. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions.

Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers. The diagnostic imaging portfolio is completed by a range of medical devices and advanced administration systems for contrast imaging products.

The company operates in over 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. Bracco Imaging has a strong presence in key geographies: North America, China, Europe, Japan, Brazil, Mexico and South Korea.

Bracco Imaging’s manufacturing plants operate in full compliance with the best practices and with sustainable eco-friendly production processes. Manufacturing sites are located in Italy, Switzerland, Germany, Canada, China and Japan.

Bracco Imaging has a well skilled and an innovative Research and Development (R&D) organization with an efficient process-oriented approach and a track record in the diagnostic imaging industry. R&D activities are located in three centers based in Italy, Switzerland and the USA. To learn more about Bracco Imaging, visit www.braccoimaging.com.